Goldman Sachs Group Inc Citius Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.48 - $1.02 $551,337 - $1.17 Million	-1,148,619 Reduced 96.8%	37,940 $18,000
Q2 2024 Aug 13, 2024	BUY	$0.58 - $1.03 $637,462 - $1.13 Million	1,099,074 Added 1256.3%	1,186,559 $688,000
Q1 2024 May 15, 2024	SELL	$0.6 - $0.9 $3,043 - $4,564	-5,072 Reduced 5.48%	87,485 $78,000
Q4 2023 Feb 13, 2024	SELL	$0.65 - $0.86 $40,127 - $53,091	-61,734 Reduced 40.01%	92,557 $70,000
Q3 2023 May 14, 2024	BUY	$0.65 - $1.25 $40,127 - $77,167	61,734 Added 66.7%	154,291 $104,000
Q3 2023 Nov 14, 2023	SELL	$0.65 - $1.25 $57,304 - $110,201	-88,161 Reduced 36.36%	154,291 $104,000
Q2 2023 May 14, 2024	BUY	$1.08 - $1.65 $247,440 - $378,034	229,112 Added 1717.48%	242,452 $290,000
Q2 2023 Aug 14, 2023	BUY	$1.08 - $1.65 $261,848 - $400,045	242,452 New	242,452 $290,000
Q4 2022 May 14, 2024	SELL	$0.79 - $1.28 $164,253 - $266,132	-207,916 Reduced 93.97%	13,340 $10,000
Q4 2022 Feb 13, 2023	BUY	$0.79 - $1.28 $10,538 - $17,075	13,340 New	13,340 $10,000
Q2 2022 May 14, 2024	BUY	$0.88 - $1.87 $113,255 - $240,667	128,699 Added 139.05%	221,256 $203,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.87 $63,555 - $135,055	72,222 Added 48.46%	221,256 $203,000
Q1 2022 May 16, 2022	BUY	$1.38 - $1.89 $125,094 - $171,324	90,648 Added 155.26%	149,034 $267,000
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.2 $209,489 - $305,217	-138,735 Reduced 70.38%	58,386 $90,000
Q3 2021 Nov 10, 2021	BUY	$1.74 - $2.6 $342,990 - $512,514	197,121 New	197,121 $401,000

2.32M

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $384M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.